Disease-driven T cell activation predicts immune responses to vaccination against melanoma
DE Speiser, D Rimoldi, P Batard, D Liénard, F Lejeune… - Cancer Immunity, 2003 - AACR
DE Speiser, D Rimoldi, P Batard, D Liénard, F Lejeune, JC Cerottini, P Romero
Cancer Immunity, 2003•AACRTumor vaccines may induce activation and expansion of specific CD8 T cells which can
subsequently destroy tumor cells in cancer patients. This phenomenon can be observed in
approximately 5-20% of vaccinated melanoma patients. We searched for factors associated
with T cell responsiveness to peptide vaccines. Peptide antigen-specific T cells were
quantified and characterized ex vivo before and after vaccination. T cell responses occurred
primarily in patients with T cells that were already pre-activated before vaccination. Thus …
subsequently destroy tumor cells in cancer patients. This phenomenon can be observed in
approximately 5-20% of vaccinated melanoma patients. We searched for factors associated
with T cell responsiveness to peptide vaccines. Peptide antigen-specific T cells were
quantified and characterized ex vivo before and after vaccination. T cell responses occurred
primarily in patients with T cells that were already pre-activated before vaccination. Thus …
Abstract
Tumor vaccines may induce activation and expansion of specific CD8 T cells which can subsequently destroy tumor cells in cancer patients. This phenomenon can be observed in approximately 5-20% of vaccinated melanoma patients. We searched for factors associated with T cell responsiveness to peptide vaccines. Peptide antigen-specific T cells were quantified and characterized ex vivo before and after vaccination. T cell responses occurred primarily in patients with T cells that were already pre-activated before vaccination. Thus, peptide vaccines can efficiently boost CD8 T cells that are pre-activated by endogenous tumor antigen. Our results identify a new state of T cell responsiveness and help to explain and predict tumor vaccine efficacy.
AACR